In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Glioblastoma Multiforme (GBM).

In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination ...

Nivolumab plus ipilimumab and nivolumab alone have been shown to improve survival, as compared with ipilimumab alone, in advanced melanoma. New research findings over 10 years of follow-up are ...

A total of 221 patients were concurrently randomly assigned to nivolumab plus ipilimumab (n = 113) or chemotherapy (n = 108). At a median follow-up of 49.2 months, the median EFS was 54.8 months (95% ...

Top-line, phase 3 results for Bristol-Myers Squibb's humanized monoclonal antibody (mAb) ipilimumab showed a survival benefit in patients with advanced cancer—the first ever phase 3 trial to do so.

"Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204." How would you ...